ATAZANAVIR AND RIFAMPIN IN HEALTHY HIV-SERONEGATIVE VOLUNTEERS

阿扎那韦和利福平在健康 HIV 血清阴性志愿者中的应用

• 批准号: 7605220
• 负责人: ANDREW RICHARD ZOLOPA
• 金额: $ 4.74万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605220
• 关键词: Atazanavir; Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Funding; Grant; Institution; Label; Pharmaceutical Preparations; Research; Research Personnel; Resources; Rifampin; Safety; Source; United States National Institutes of Health; Upper arm; day; volunteer

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5213 is an open-label, single-arm, pharmacokinetic (PK) interaction study of atazanavir (ATV) and rifampin (RIF) in healthy, HIV-seronegative volunteers. Safety and tolerability will be assessed during the study. Each subject who completes the study will have received study drugs for at least 27 days but no more than 37 days.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 A5213是一项在健康HIV血清阴性志愿者中进行的阿扎那韦（ATV）和利福平（RIF）的开放标签、单组、药代动力学（PK）相互作用研究。 将在研究期间评估安全性和耐受性。完成研究的每例受试者将接受研究药物至少27天但不超过37天。